2018), no disease modifying therapies are yet available (Espay et al
Lilly and peer-reviewed clinical literature consistently describe Tirzepatide as a once-weekly dual GIP/GLP-1 receptor agonist with strong effects on glycaemic and body-weight outcomes in human studies
The resulting decrease in cell volume concentrates intracellular K + ions, which increases the driving force for efflux of potassium out of cells and into the blood stream through potassium permeable ion channels
Elssner, T., Preusser, A., Wagner, U
In addition, inhibiting the expression of SLC7A11 gene will affect the synthesis of glutathione, thereby causing the apoptosis of IDH1 mutant glioma cells
The pain might not be from the drug itself but could be linked to other body changes that happen while using the medication, like dehydration, nausea, or grinding teeth at night